Drug intelligence / Profile preview

lefradafiban

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

Lefradafiban is an orally active small molecule prodrug of fradafiban and acts as a Glycoprotein IIb/IIIa receptor antagonist. It was developed for the treatment of unstable angina and other forms of coronary artery disease. Lefradafiban works by blocking the final common pathway of platelet aggregation through inhibition of the Glycoprotein IIb/IIIa receptor on platelets. This mechanism prevents platelet aggregation and thrombus formation in patients at risk for acute coronary syndromes. Clinical development reached phase 2 trials but was discontinued due to lack of efficacy[1][4][7].

Other names: lefradafibánléfradafibanlefradafibanum

Targets

GPIIb/IIIa (Integrin alpha-IIb/beta-3)

Beyond the preview

Go deeper on lefradafiban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lefradafiban.

Explore the full profile